Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Plan S: A threat to quality of science?

Spedding M, Barrett J, Morgan ET, Vore M, Geraghty D, Kirkpatrick C, Cascorbi I.

Science. 2019 Feb 1;363(6426):462. doi: 10.1126/science.aaw1424. No abstract available.

PMID:
30705177
2.

Interaction of herbal products with prescribed medications: A systematic review and meta-analysis.

Awortwe C, Bruckmueller H, Cascorbi I.

Pharmacol Res. 2019 Jan 17;141:397-408. doi: 10.1016/j.phrs.2019.01.028. [Epub ahead of print] Review.

PMID:
30660822
3.

The Nomenclature, Definition and Distinction of Types of Shock.

Standl T, Annecke T, Cascorbi I, Heller AR, Sabashnikov A, Teske W.

Dtsch Arztebl Int. 2018 Nov 9;115(45):757-768. doi: 10.3238/arztebl.2018.0757.

4.

In Reply.

Böhm R, Cascorbi I, Proksch E, Schwarz T.

Dtsch Arztebl Int. 2018 Oct 19;115(42):713. doi: 10.3238/arztebl.2018.0713b. No abstract available.

5.

The Neurophysiology and Treatment of Motion Sickness.

Koch A, Cascorbi I, Westhofen M, Dafotakis M, Klapa S, Kuhtz-Buschbeck JP.

Dtsch Arztebl Int. 2018 Oct 12;115(41):687-696. doi: 10.3238/arztebl.2018.0687.

6.

Retinoic acid-induced survival effects in SH-SY5Y neuroblastoma cells.

Waetzig V, Haeusgen W, Andres C, Frehse S, Reinecke K, Bruckmueller H, Boehm R, Herdegen T, Cascorbi I.

J Cell Biochem. 2019 Apr;120(4):5974-5986. doi: 10.1002/jcb.27885. Epub 2018 Oct 15.

PMID:
30320919
7.

Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis.

Erdmann P, Bruckmueller H, Martin P, Busch D, Haenisch S, Müller J, Wiechowska-Kozlowska A, Partecke LI, Heidecke CD, Cascorbi I, Drozdzik M, Oswald S.

J Pharm Sci. 2019 Feb;108(2):1035-1046. doi: 10.1016/j.xphs.2018.09.024. Epub 2018 Sep 26.

PMID:
30267783
8.

SIGMA-1 Receptor Gene Variants Affect the Somatosensory Phenotype in Neuropathic Pain Patients.

Sachau J, Bruckmueller H, Gierthmühlen J, Magerl W, Kaehler M, Haenisch S, Binder A, Caliebe A, Maier C, Treede RD, Tölle T, Cascorbi I, Baron R.

J Pain. 2019 Feb;20(2):201-214. doi: 10.1016/j.jpain.2018.08.011. Epub 2018 Sep 25.

PMID:
30266269
9.

Drug Hypersensitivity.

Böhm R, Proksch E, Schwarz T, Cascorbi I.

Dtsch Arztebl Int. 2018 Jul 23;115(29-30):501-512. doi: 10.3238/arztebl.2018.0501.

10.

The Pharmacogenetics of Immune-Modulating Therapy.

Cascorbi I.

Adv Pharmacol. 2018;83:275-296. doi: 10.1016/bs.apha.2018.02.004. Epub 2018 Mar 30.

PMID:
29801578
11.

Significance of Pharmacogenomics in Precision Medicine.

Cascorbi I.

Clin Pharmacol Ther. 2018 May;103(5):732-735. doi: 10.1002/cpt.1052.

PMID:
29660122
12.

MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.

Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I, Bruckmueller H.

Oncotarget. 2017 Sep 26;8(54):92018-92031. doi: 10.18632/oncotarget.21272. eCollection 2017 Nov 3.

13.

MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2.

Awortwe C, Kaehler M, Rosenkranz B, Cascorbi I, Bruckmueller H.

Xenobiotica. 2018 Oct;48(10):1050-1058. doi: 10.1080/00498254.2017.1390624. Epub 2017 Nov 2.

PMID:
28990842
14.

Inflammation: Treatment Progress and Limitations.

Cascorbi I.

Clin Pharmacol Ther. 2017 Oct;102(4):564-567. doi: 10.1002/cpt.792.

PMID:
28895120
15.

Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H, Ottmann O, Pfeifer H, Trautmann H, Gökbuget N, Caliebe A, Kabelitz D, Kneba M, Horst HA, Hoelzer D, Topp MS, Cascorbi I, Siebert R, Brüggemann M.

Blood. 2017 Nov 2;130(18):2027-2031. doi: 10.1182/blood-2017-05-782888. Epub 2017 Aug 21.

16.

Short Report: TRPV1-polymorphism 1911 A>G alters capsaicin-induced sensory changes in healthy subjects.

Forstenpointner J, Förster M, May D, Hofschulte F, Cascorbi I, Wasner G, Gierthmühlen J, Baron R.

PLoS One. 2017 Aug 17;12(8):e0183322. doi: 10.1371/journal.pone.0183322. eCollection 2017.

17.

Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?

Culman J, Jacob T, Schuster SO, Brolund-Spaether K, Brolund L, Cascorbi I, Zhao Y, Gohlke P.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Sep;390(9):949-959. doi: 10.1007/s00210-017-1395-y. Epub 2017 Jul 2.

PMID:
28669009
18.

Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.

Bruckmueller H, Martin P, Kähler M, Haenisch S, Ostrowski M, Drozdzik M, Siegmund W, Cascorbi I, Oswald S.

Mol Pharm. 2017 Jul 3;14(7):2245-2253. doi: 10.1021/acs.molpharmaceut.7b00076. Epub 2017 Jun 2.

PMID:
28510455
19.

Neurodegenerative effects of azithromycin in differentiated PC12 cells.

Waetzig V, Riffert J, Cordt J, Reinecke K, Haeusgen W, Boehm R, Cascorbi I, Herdegen T.

Eur J Pharmacol. 2017 Aug 15;809:1-12. doi: 10.1016/j.ejphar.2017.05.002. Epub 2017 May 4.

PMID:
28479141
20.

Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells.

Waetzig V, Belzer M, Haeusgen W, Boehm R, Cascorbi I, Herdegen T.

Mol Cell Neurosci. 2017 Jul;82:12-22. doi: 10.1016/j.mcn.2017.04.004. Epub 2017 Apr 14.

PMID:
28414095
21.

Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPARγ - dependent mechanism.

LÜtzen U, Zhao Y, Lucht K, Zuhayra M, Hedderich J, Cascorbi I, Culman J.

Neoplasma. 2017;64(3):395-405. doi: 10.4149/neo_2017_310.

PMID:
28253719
22.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

23.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

24.

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.

Böhm R, Cascorbi I.

Front Pharmacol. 2016 Oct 21;7:396. eCollection 2016. Review.

25.

Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Lützen U, Zhao Y, Lucht K, Zuhayra M, Marx M, Cascorbi I, Culman J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):37-48. doi: 10.1007/s00210-016-1291-x. Epub 2016 Sep 23.

PMID:
27664035
26.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

27.

miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model.

Haenisch S, von Rüden EL, Wahmkow H, Rettenbeck ML, Michler C, Russmann V, Bruckmueller H, Waetzig V, Cascorbi I, Potschka H.

ACS Chem Neurosci. 2016 Nov 16;7(11):1585-1594. Epub 2016 Sep 22.

PMID:
27609046
28.

Advances and challenges in hereditary cancer pharmacogenetics.

Cascorbi I, Werk AN.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):73-82. Epub 2016 Sep 16. Review.

PMID:
27603572
29.

Epigenetics in Drug Response.

Cascorbi I, Schwab M.

Clin Pharmacol Ther. 2016 May;99(5):468-70. doi: 10.1002/cpt.349.

PMID:
27061003
30.

HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.

Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium.

Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209.

PMID:
26959717
31.

Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance.

Bruhn O, Drerup K, Kaehler M, Haenisch S, Röder C, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):327-40. doi: 10.2217/pgs.15.175. Epub 2016 Feb 19.

PMID:
26895184
32.

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Schirmer JH, Bremer JP, Moosig F, Holle JU, Lamprecht P, Wieczorek S, Haenisch S, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):367-74. doi: 10.2217/pgs.15.176. Epub 2016 Feb 19.

PMID:
26894931
33.

Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?

Ingelman-Sundberg M, Cascorbi I.

Clin Pharmacol Ther. 2016 May;99(5):478-80. doi: 10.1002/cpt.351. Epub 2016 Mar 29.

PMID:
26874931
34.

Targeting gene expression during the early bone healing period in the mandible: A base for bone tissue engineering.

Beck-Broichsitter BE, Werk AN, Smeets R, Gröbe A, Heiland M, Cascorbi I, Wiltfang J, Häsler R, Becker ST.

J Craniomaxillofac Surg. 2015 Oct;43(8):1452-60. doi: 10.1016/j.jcms.2015.06.015. Epub 2015 Jun 23.

PMID:
26189147
35.

SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.

Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL.

Neurobiol Dis. 2015 May;77:127-40. doi: 10.1016/j.nbd.2015.02.025. Epub 2015 Mar 10.

36.

Pharmacological treatment of pain: future trends and novel insights.

Cascorbi I.

Clin Pharmacol Ther. 2015 Feb;97(2):104-8. doi: 10.1002/cpt.25.

PMID:
25670508
37.

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.

Haroun F, Al-Shaar L, Habib RH, El-Saghir N, Tfayli A, Bazarbachi A, Salem Z, Shamseddine A, Taher A, Cascorbi I, Zgheib NK.

Cancer Chemother Pharmacol. 2015 Jan;75(1):207-14. doi: 10.1007/s00280-014-2632-4. Epub 2014 Nov 27.

PMID:
25428516
38.

Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.

Bruckmueller H, Werk AN, Renders L, Feldkamp T, Tepel M, Borst C, Caliebe A, Kunzendorf U, Cascorbi I.

Ther Drug Monit. 2015 Jun;37(3):288-95. doi: 10.1097/FTD.0000000000000142.

PMID:
25271728
39.

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.

Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF.

Nat Commun. 2014 Sep 4;5:4757. doi: 10.1038/ncomms5757.

40.

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.

Bruhn O, Cascorbi I.

Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1337-54. doi: 10.1517/17425255.2014.952630. Epub 2014 Aug 27. Review.

PMID:
25162314
41.

Functional gene variants of CYP3A4.

Werk AN, Cascorbi I.

Clin Pharmacol Ther. 2014 Sep;96(3):340-8. doi: 10.1038/clpt.2014.129. Epub 2014 Jun 13. Review.

PMID:
24926778
42.

Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.

Werk AN, Bruckmueller H, Haenisch S, Cascorbi I.

Pharmacogenet Genomics. 2014 Jun;24(6):283-91. doi: 10.1097/FPC.0000000000000046.

PMID:
24743544
43.

MicroRNAs and their relevance to ABC transporters.

Haenisch S, Werk AN, Cascorbi I.

Br J Clin Pharmacol. 2014 Apr;77(4):587-96. doi: 10.1111/bcp.12251. Review.

44.

Progress in pharmacogenomics: bridging the gap from research to practice.

Cascorbi I, Tyndale R.

Clin Pharmacol Ther. 2014 Mar;95(3):231-5. doi: 10.1038/clpt.2013.235.

PMID:
24548984
45.

Opportunities and limitations: the value of pharmacogenetics in clinical practice.

Daly AK, Cascorbi I.

Br J Clin Pharmacol. 2014 Apr;77(4):583-6. doi: 10.1111/bcp.12354. No abstract available.

46.

Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.

Ott G, Reichmann D, Boerger C, Cascorbi I, Bittner F, Mendel RR, Kunze T, Clement B, Havemeyer A.

Drug Metab Dispos. 2014 Apr;42(4):718-25. doi: 10.1124/dmd.113.055202. Epub 2014 Jan 14.

PMID:
24423752
47.

Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.

Oberstadt MC, Bien-Möller S, Weitmann K, Herzog S, Hentschel K, Rimmbach C, Vogelgesang S, Balz E, Fink M, Michael H, Zeden JP, Bruckmüller H, Werk AN, Cascorbi I, Hoffmann W, Rosskopf D, Schroeder HW, Kroemer HK.

BMC Cancer. 2013 Dec 31;13:617. doi: 10.1186/1471-2407-13-617.

48.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

49.

Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics.

Cascorbi I.

Pharmacogenomics. 2013 Nov;14(15):1807-9. doi: 10.2217/pgs.13.194. No abstract available.

50.

Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance.

Werk AN, Lefeldt S, Bruckmueller H, Hemmrich-Stanisak G, Franke A, Roos M, Küchle C, Steubl D, Schmaderer C, Bräsen JH, Heemann U, Cascorbi I, Renders L.

Clin Pharmacol Ther. 2014 Apr;95(4):416-22. doi: 10.1038/clpt.2013.210. Epub 2013 Oct 14. Erratum in: Clin Pharmacol Ther. 2014 Nov;96(5):625. Clin Pharmacol Ther. 2014 Nov;96(5):625.

PMID:
24126681

Supplemental Content

Loading ...
Support Center